Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 18, 2025, covering a share repurchase executed on March 17, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme under a non-discretionary agreement entered into on February 24, 2025.
Key Financial Metrics
- Shares Purchased (March 17, 2025): 745,425 ordinary shares.
- Price Range: Lowest price paid was 1,509.50 GBp; highest price paid was 1,537.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,524.47 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: 180,276,770 ordinary shares (post-transaction).
- Shares in Issue (excluding Treasury): 4,134,928,522 ordinary shares.
- Total Voting Rights: 4,134,928,522.
- Cumulative Buyback (since Feb 24, 2025): 11,206,467 ordinary shares.
Material Changes
The filing details a reduction in the number of shares in issue due to the purchase of 745,425 shares for treasury. This represents a continuation of the buyback programme initiated on February 24, 2025. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period, as it is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Specific risk factors are referenced as being detailed on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F. No new guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (180,276,770) against the company's latest capital structure disclosures.
- Confirm the remaining capacity under the current buyback programme announced on February 24, 2025.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors referenced in the cautionary statement.
- Monitor subsequent filings for updates on the cumulative volume of shares repurchased under the non-discretionary agreement.